Lee, Inyoung http://orcid.org/0000-0001-5436-2013
Jokinen, Jeremy D. http://orcid.org/0000-0001-8484-5788
Crawford, Stephanie Y. http://orcid.org/0000-0002-0228-337X
Calip, Gregory S. http://orcid.org/0000-0002-7744-3518
Kilpatrick, Ryan D.
Lee, Todd A. http://orcid.org/0000-0003-3619-5367
Article History
Received: 7 April 2020
Accepted: 14 July 2020
First Online: 27 July 2020
Compliance with Ethical Standards
:
: Inyoung Lee was supported by the UIC-AbbVie Fellowship in Pharmacovigilance and Patient Safety. Jeremy D. Jokinen was employed by AbbVie, Inc. and owned stocks of the company while the submitted work was conducted; and currently is an employee and shareholder of Bristol-Myers Squibb Company. Gregory S. Calip received grants from AbbVie, Inc. and Pfizer, Inc. outside the submitted work; and at the time of publication, reports current employment with Flatiron Health, Inc., which is an independent subsidiary of the Roche group. Ryan D. Kilpatrick is an employee of AbbVie, Inc. and may own stocks of the company. All other authors have no conflicts of interest to disclose.